Management of comorbidities in chronic kidney disease: A prospective observational study

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 2, 2014, Pages 363-367

  Dasari, Pranavi ^a   Venkateshwarlu, K ^a   Venisetty, Raj Kumar ^b  

^a ST PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

^b Chaitanya College of Pharmacy Education and Research   (India)

Author keywords

Comorbidities; Coronary artery disease; Diabetes mellitus; Hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; DIURETIC AGENT; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; IRON SACCHARATE; ROSUVASTATIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

EID: 84897143070     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chadban S, Briganti E, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of Kidney Damage in Australian Adults: The AusDiab Kidney Study. J Am Soc Nephrol 2003; 14 Suppl 2: S131-S138.
2. Moeller S, Gioberge S, Brown G. ESRD patients in 2001: Global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002; 17: 2071-2076.
3. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. New Eng J Med 2010; 362: 56-65.
4. National Institute for Health Care and Excellence. Chronic Kidney Disease. NICE clinical guideline 73, 2008. Available on www. guidance. nice. org. uk.
5. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885.
6. Levin A. Identification of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001; 16: 57-60.
7. Stevens AL, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and Comorbid Illness in Elderly Patients in the United States: Results From the Kidney Early Evaluation Program (KEEP). Am J Kidney Diseases 2010; 55: S23-S33.
8. Kaisar M, Isbel N, Johnson DW. Cardiovascular disease in patients with chronic kidney disease. A clinical review. Ita J Urol Nephrol 2007; 59: 281-297.
9. Cavanaugh Kl. Diabetes management issues for patients with chronic kidney disease. Clin diab 2007; 25: 90-97.
10. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Primary Care 2008; 35: 329-344.
11. Nolan MS, Podoll AS, Hause AM, Akers KM, Finkel KW, Murray KO. Prevalence of CKD and progression of disease over time among patients enrolled in the Houston west nile virus cohort. PloS One 2012; 7: e40374.
12. Toto RD. Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. J Clin Hypertension 2005; 7 Suppl 1: 15-20.
13. Coats WC, Baig SZ, Alpert MA, Aggarwal K. Management of Coronary Artery Disease in Patient with Chronic Kidney Disease. Adv Peritoneal Dial 2009; 25: 125-128.
14. Pinevich AJ, Petersen J. Erythropoietin Therapy in Patients with Chronic Renal Failure, Western J Med 1992; 157: 154-157.
15. Weinhandl Ed, Rao M, Gilbertson DT, Collins AJ, Pereira BJ. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients. 1998-2003. Am J Kidney Dis 2007; 50: 803-812.
16. Kanbay M, Turgut F, Covic A, Goldsmith D. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 2009; 22: 508-609.
17. Strippoli GFM, Navaneethan SD, Johnson DW, Perkovic V, Pellegrinin F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. British Med J 2008; 336: 645-651.
18. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syn 2010; 2: 44-54.